Table 1.
Clinical trials initiated with Tim-3 antibodies.
| Clinical Trials.gov Identifier | Reagent Name | Co-Blockade | Cancer | Manufacturer | Year |
|---|---|---|---|---|---|
| NCT02608268 | MGB453 | Anti PD-1 | Patients with advanced cancer | Novartis Pharmaceuticals | 2015 |
| NCT02817633 | TSR-022 | Anti PD-1 | Patients with advanced solid tumors | Tesaro, Inc. | 2016 |
| NCT03066648 | MGB453 | Monotherapy/anti-PD-1/Hypomethylating agent | MDS/AML | Novartis Pharmaceuticals | 2017 |
| NCT030680508 | TSR-022 | Anti PD-1 | Liver cancer | Tesaro, Inc. | 2016 |
| NCT03099109 | LY3321367 | Anti PD-L1 | Advanced solid tumors (relapsed/refractory) | Eli Lilly and Company | 2019 |
|
NCT03311412 NCT03489343 |
Sym023 | Anti PD-1/Monotherapy | Lymphomas and solid tumors | Symphogen | 2018 |
| NCT03708328 | R07121661 | TIM-3 and PD-1 | Solid tumors metastatic melanoma | Hoffmann-La Roche | 2019 |
| NCT03744468 | BGBA425 | Anti PD-1 | Solid tumors | BeiGene | 2017 |
| NCT03946670 | MGB453 | MDS | Randomized/HMA | Novartis Pharmaceuticals | 2019 |